迪瑞医疗科技股份有限公司 证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-053 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）于2023年05月09日召开的 2022年年度股东大会审议通过了《关于回购注销2021年限制性股票激励计划部分 激励对象已获授但尚未解除限售的限制性股票的议案》《关于回购注销2022年限 制性股票激励计划部分激励对象已获授但尚未解除限售的限制性股票的议案》 《关于减少公司注册资本的议案》等议案。2023年07月07日，公司披露了《关于 部分限制性股票回购注销完成的公告》。具体内容详见公司披露于巨潮资讯网 （www.cninfo.com.cn）上的相关公告。 近日，公司完成了注册资本变更等相关的工商变更登记工作，并取得由长春 市市场监督管理局长春新区分局换发的《营业执照》。 《营业执照》登记的相关信息如下： 注册号：91220101605902656F 名称：迪瑞医疗科技股份有限公司 特此公告。 迪瑞医疗科技股份有限公司董事会 法定代表人：王学敏 ...

迪瑞医疗科技股份有限公司 关于持股 5%以上股东减持股份计划减持时间过半的公告 证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-052 持股 5%以上的广东恒健国际投资有限公司保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 迪瑞医疗科技股份有限公司（以下简称"公司"） 于 2023 年 6 月 2 日披露 了《关于持股 5%以上股东减持股份预披露公告》。"公司持股 5%以上股东广东恒 健国际投资有限公司（以下简称"恒健国际"）计划以竞价方式减持公司股份合 计不超过 2,752,083 股，减持股份数量不超过公司总股本 1%，自本减持计划公 告之日起十五个交易日后的三个月内实施。" （以下简称"本次减持计划"） 公司接到持股 5%以上股东恒健国际的通知，截至目前，恒健国际本次减持 计划减持时间已过半，根据《上市公司股东、董监高减持股份的若干规定》《深 圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》等 相关规定，现将上述股东拟减持股份进展情况公告如下： 一、 股东减持情况 ...

迪瑞医疗科技股份有限公司（以下简称"公司"）于近日收到第五届董事会 董事黄晓光先生的辞职报告，其因工作调整原因辞去公司董事及审计委员会委员 职务。黄晓光先生的辞职不会导致公司董事会人数低于法定最低人数，不会影响 公司董事会的正常运作，黄晓光先生关于辞去公司董事的辞职报告自送达董事会 之日起生效。黄晓光先生辞职后将不在公司任职。 黄晓光先生担任的董事职务原定任期为第五届董事会届满之日（2023 年 12 月 27 日）止。截至公告披露日，黄晓光先生未持有公司股份，其将继续遵守《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司股东及董事、监 事、高级管理人员减持股份实施细则》等法律法规和业务规则中关于持有公司股 份的相关规定及其所作的相关承诺。 公司董事会对黄晓光先生在担任公司董事期间为公司发展做出的贡献表示 衷心的感谢！ 特此公告。 证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-051 迪瑞医疗科技股份有限公司 关于公司董事辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、 ...

证券代码：300396 证券简称：迪瑞医疗 迪瑞医疗科技股份有限公司 投资者关系活动记录表 编号：2023-004 投资者关系活 √特定对象调研 □分析师会议 动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 √其他 电话会议 | --- | --- | --- | --- | |------------|--------------|------------|--------------| | 安信基金 | 北京润晖 | 博迈基金 | 博时基金 | | 财通基金 | 丹羿投资 | 德邦证券 | 德邦资管 | | 东北证券 | 东方基金 | 东方证券 | 东莞证券资管 | | 东吴基金 | 东亚前海 | 东证资管 | 富国基金 | | 歌斐诺宝 | 工银瑞信 | 观澜湖投资 | 光大保德信 | | 光大资管 | 广发基金 | 国海证券 | 国华兴益 | | 国泰君安 | 国泰君安资管 | 国投资管 | 国信证券 | | 海创百川 | 海富通基金 | 恒越基金 | 横越基金 | | 弘尚资管 | 弘毅远方 | 红土基金 | 泓澄投资 | | 华安基金 | 华宝基金 | 华创证券 | 华创资 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,220,007,787.71, representing a 34.69% increase compared to ¥905,795,040.28 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥261,723,955.32, a 24.66% increase from ¥209,948,414.77 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥248,983,421.75, up 32.68% from ¥187,658,243.93 in 2021[20]. - The basic earnings per share for 2022 was ¥0.96, an increase of 26.32% from ¥0.76 in 2021[20]. - The total assets at the end of 2022 amounted to ¥2,925,260,842.41, a 23.14% increase from ¥2,375,626,201.07 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were ¥1,919,777,945.59, reflecting a 2.31% increase from ¥1,876,348,953.10 in 2021[20]. - The cash flow from operating activities for 2022 was ¥40,924,699.36, a significant decrease of 75.55% compared to ¥167,412,927.13 in 2021[20]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[48]. - The gross margin improved to 45%, up from 40% in the previous year, indicating better cost management and pricing strategies[48]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year growth of 20%[161]. Market Expansion and Strategy - The company is focusing on technological upgrades and market expansion as part of its "14th Five-Year Plan" strategy to enhance healthcare levels in China[32]. - The company is positioned to benefit from government policies aimed at enhancing healthcare infrastructure and increasing procurement demand for medical devices[31]. - The company has established a sales and service network in over 120 countries and regions, enhancing its international market presence[39]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[48]. - The company is actively pursuing partnerships and collaborations to strengthen its market position and drive growth[46]. - The company aims to enhance the motivation of its management and core technical teams by optimizing the assessment system to ensure the early achievement of the "14th Five-Year" strategic goals[116]. - The company plans to enhance its distribution network, aiming to increase the number of distribution partners by 30% in the next year[48]. Research and Development - The company has maintained a commitment to independent research and development, ensuring all its high-end instrument products possess independent intellectual property rights[32]. - The company has established a strong R&D team with 304 technical personnel across various fields, and has received approval to set up a post-doctoral research workstation, enhancing collaboration with academic institutions[45]. - The company invested approximately ¥114.34 million in R&D in 2022, representing 9.37% of its operating revenue[81]. - The company launched several new products, including the fully automated chemiluminescence immunoassay analyzer and the BF-7600 automated blood fluid analyzer, enhancing its high-end product offerings[80]. - The company is focusing on the development of integrated laboratory products, including the LA-60 fully automated sample processing system, which intelligently allocates sample paths to avoid congestion[42]. - The company is committed to ongoing research and development to improve the accuracy and reliability of its diagnostic products[50]. - The company is strategically positioning itself for future growth by diversifying its product offerings and enhancing its technological capabilities in medical testing[91]. Product Development and Innovation - The company has launched a total of 10 new products in 2022, including clinical chemistry quality control blood products and automatic gynecological secretion analysis systems[53]. - The company is focusing on expanding its product line with new diagnostic kits, including those for thyroid hormones and other key biomarkers, enhancing its market presence in the healthcare sector[84]. - The company has developed a comprehensive laboratory automation system to improve testing efficiency and reduce labor costs[36]. - The company is actively involved in the development of new technologies, particularly in the field of immunoassay and biochemical analysis[85]. - The company aims to leverage its new product launches to capture a larger share of the healthcare diagnostics market[84]. - The company is focused on expanding its product line with new testing kits for various biomarkers, including procalcitonin and B-type natriuretic peptide, enhancing its diagnostic capabilities[91]. Financial Management and Governance - The company has a complete independent labor and personnel management system, with no overlapping roles with controlling shareholders[139]. - The company has established a governance structure that includes a general meeting, board of directors, and supervisory board, ensuring clear responsibilities and compliance with regulations[134]. - The company has maintained a transparent information disclosure process, ensuring timely and accurate communication with investors[135]. - The company has a structured remuneration scheme for its senior management based on their roles and performance, ensuring alignment with company standards[157]. - The company is focused on maintaining compliance with relevant laws and regulations regarding remuneration and governance practices[157]. - The company has established an effective environmental management system, with no environmental accidents reported during the reporting period[192]. Challenges and Risks - The company faces risks from strict industry regulations and policies, which could adversely affect its operations if it fails to adapt to changes in domestic and export market policies[123]. - The company recognizes the risk of intensified market competition in the in vitro diagnostics sector and aims to innovate and strengthen its competitive advantages through product development and strategic partnerships[124]. - The company is enhancing its foreign exchange risk management mechanisms to address potential impacts from international market fluctuations and currency exchange rate volatility[127]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of ¥4.8 per 10 shares (including tax) to all shareholders[3]. - The total cash dividend amount, including other methods, is RMB 182,100,446.34, which accounts for 100% of the distributable profit[172]. - The company has implemented an employee stock ownership plan and stock incentive plan, with the first phase of the 2021 stock incentive plan completed[173]. - The company has established a performance evaluation mechanism for senior management and implemented stock incentive plans to enhance corporate governance and attract talent[183].

Financial Performance - The company's revenue for Q1 2023 was ¥331,932,094.69, representing a 46.54% increase compared to ¥226,514,694.52 in the same period last year[5] - Net profit attributable to shareholders was ¥77,711,739.74, up 27.79% from ¥60,813,979.13 year-on-year[5] - The company achieved a basic earnings per share of ¥0.2865, reflecting a 29.17% increase from ¥0.2218 in the same period last year[5] - Total operating revenue for Q1 2023 reached ¥331,932,094.69, a significant increase of 46.6% compared to ¥226,514,694.52 in the same period last year[23] - Operating profit for Q1 2023 was ¥85,536,589.74, representing a 27.1% increase from ¥67,273,409.04 in the previous year[23] - The total comprehensive income for the first quarter was approximately ¥77.11 million, compared to ¥60.54 million in the same period last year[24] Cash Flow - The net cash flow from operating activities improved significantly, reaching -¥5,927,387.04, a 79.86% increase from -¥29,426,149.07 in the previous year[5] - Cash flow from operating activities showed a net outflow of approximately ¥5.93 million, an improvement from a net outflow of ¥29.43 million in Q1 2022[26] - The company reported cash inflows from investment activities of approximately ¥193.31 million, a decrease from ¥572.60 million in the same quarter last year[26] - The net cash flow from financing activities was negative at approximately ¥3.03 million, compared to a negative cash flow of ¥49.94 million in Q1 2022[27] - The company experienced a foreign exchange loss impacting cash and cash equivalents of approximately ¥2.10 million during the quarter[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,995,901,600.82, a 2.41% increase from ¥2,925,260,842.41 at the end of the previous year[5] - Current assets totaled ¥1,855,503,424.29 at the end of the period, an increase from ¥1,828,452,182.29 at the beginning of the year[20] - The company’s total liabilities decreased to ¥991,927,746.93 from ¥1,005,435,860.00, indicating a reduction of 1.3%[21] - Cash and cash equivalents at the end of the period were ¥814,664,022.59, down from ¥838,136,028.79 at the beginning of the year, a decrease of 2.8%[20] - Inventory increased to ¥429,391,781.06 from ¥375,902,952.82, marking a rise of 14.2%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,048, with the largest shareholder holding 28.08% of the shares[13] - In Q1 2023, the company reported a total of 33,123,600 shares held by Guangdong Hengjian International Investment Co., accounting for 12.04% of total shares[14] - Shareholder Song Jie holds 18,633,103 shares, representing 6.77% of total shares, while Song Yong holds 11,091,800 shares, or 4.03%[14] - The company’s major shareholders include China Construction Bank with 13,500,000 shares (4.91%) and other investment funds holding significant stakes[14] - As of March 31, 2023, the total number of restricted shares held by Song Jie decreased by 5,626,650 shares, leaving 17,009,070 shares[17] Expenses and Investments - The company reported a significant increase in sales expenses, which rose by 106.97% to ¥5,487,000, primarily due to increased personnel costs and market expansion efforts[10] - The investment income increased by 27.77% to ¥831,000, attributed to higher returns from investments in Ningbo Ruiyuan[10] - The company invested ¥22,230,348.74 in R&D during Q1 2023, compared to ¥20,677,466.87 in the same period last year, showing an increase of 7.5%[23] Other Financial Metrics - The company recorded a decrease in cash flow from investing activities, which fell by 110.92% to -¥14,134,470.00, mainly due to a reduction in the redemption of financial products[11] - The company reported a net profit attributable to shareholders of ¥1,282,855,282.37, up from ¥1,205,049,756.63 at the beginning of the year, reflecting a growth of 6.4%[21] - Total operating costs for Q1 2023 were ¥261,998,562.12, up 54.5% from ¥169,474,938.59 in Q1 2022[23] - The cumulative percentage of shares held by major shareholder Song Jie and her concerted parties decreased by 5.00% during the reporting period[18] - The company announced plans to adjust the repurchase price of its 2021 and 2022 restricted stock incentive plans, pending approval at the 2022 annual shareholders' meeting[18] - The company’s financial statements for Q1 2023 are compiled as of March 31, 2023, indicating ongoing financial assessments[19]

（二）中国基金报-机会宝网上路演中心 1、时间：2023 年 4 月 21 日（星期五）15：00 至 17：00； 证券代码：300396 证券简称：迪瑞医疗 公告编号：2023-027 迪瑞医疗科技股份有限公司 关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"）《2022 年年度报告》及 其摘要于 2023 年 4 月 18 日在中国证监会指定的创业板信息披露网站上披露。为 便于投资者进一步了解公司的生产经营等情况，公司拟定于 2023 年 4月 21 日（星 期五）15：00 至 17：00 采取网络远程的方式举办 2022 年年度报告网上业绩说 明会。 投资者可通过以下方式参与，具体方式如下： （一）全景•路演天下 1、时间：2023 年 4 月 21 日（星期五）15：00 至 17：00； 2、参与方式：投资者可登陆"全景•路演天下（https://ir.p5w.net）参与互动 交流。 2023 年 4 月 17 日 2、参 与 方 式 ： 投 资 者 ...